beta-glucano

Beta-Glucan: A Comprehensive Reference

1. Identity, Chemical Nomenclature, and Natural Sources

Chemical Identity

Beta-glucans (β-glucans) comprise a group of β-D-glucose polysaccharides (glucans) naturally occurring in the cell walls of plants (including cereals), bacteria, algae, and fungi, with significantly differing physicochemical properties dependent on source. The compounds that are most commonly referred to by this name are homopolymers of glucose having a linear molecule with (1→3)-β-D-glycosidic linkages or a branched one, with side chains bound by (1→6)-β-D-glycosidic linkages.

Typically, β-glucans form a linear backbone with 1–3 β-glycosidic bonds but differ with respect to molecular mass, solubility, viscosity, branching structure, and gelation properties, with several physiological roles in these organisms and causing diverse physiological effects in animals that consume them. Although chemically heterogeneous, these polysaccharides are usually termed by the common name "β-glucans." These compounds, which otherwise cause similar or nearly identical immune reactions in macroorganisms, can differ in origin as well as in their primary, secondary, or tertiary structures, and their solubility in water or alkalies.

Differences in molecular weight, shape, and structure of β-glucans dictate the differences in biological activity. Beta-glucans can be water-soluble or can exist as particulate matter depending upon their natural sources; both soluble and particulate beta-glucans are known to modify the immune landscape but via different pathways. Particulate beta-glucans involve Dectin-1-dependent mechanisms, while soluble beta-glucans mediate immune modulation by activating the CR-3-dependent pathways and the complement system.

Source-Specific Structural Distinctions

Among cereal sources, oats and barley share a chemically similar polysaccharide β-glucan, specifically (1→3),(1→4)-mixed linkage β-D-glucan. Mushroom cell walls are rich in β-glucans — long or short-chain polymers of glucose subunits with β-1,3 and β-1,6 linkages responsible for the linear and branching structures, respectively — whereas β-glucans from cereals have no 1,6 linkages nor branching structures.

Beta-glucans derived from baker's yeast, Saccharomyces cerevisiae, are made up of chains of D-glucose molecules connected at the 1 and 3 positions, having side chains of glucose attached at the 1 and 6 positions. Yeast-derived β-glucan is an insoluble, fiber-like, complex sugar having the general structure of a linear chain of glucose units with a β-1,3 backbone interspersed with β-1,6 side chains that are generally 6–8 glucose units in length. More specifically, β-glucan derived from baker's yeast is poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose.

Principal Natural Sources and Concentrations

Beta-glucans are a heterogeneous group of polysaccharides composed of D-glucose monomers linked primarily through β(1→3), β(1→4), and β(1→6) glycosidic bonds. They are naturally present in the cell walls of cereals (such as oats and barley), fungi (like mushrooms), yeasts (notably Saccharomyces cerevisiae), and certain bacterial species. Key sources include:

• Oats (Avena sativa): Depending on the specific variety, oats contain 6–8% (w/w) β-glucan.
• Barley (Hordeum vulgare): Barley contains 4–10% (w/w) β-glucan, depending on variety and environmental conditions.
• Baker's yeast (Saccharomyces cerevisiae): One of the most common sources of β-glucan for supplement use is derived from the cell wall of baker's yeast (Saccharomyces cerevisiae).
• Medicinal and edible mushrooms: Rich sources include yeasts like Saccharomyces cerevisiae and medicinal mushrooms such as shiitake and reishi, which have long been used in traditional medicine for their immune-enhancing benefits.

Common Forms and Preparations

Beta-glucans usually come as a powder that may be loose or in capsules. Oat and barley beta-glucans generally require larger doses, which is more easily achieved with a loose powder that can be added to food or beverages. Oral forms of beta-glucans are also widely available over-the-counter as oat bran and bran-based products such as breakfast cereals, cereal bars, and drinks. There are two main methods for the production of β-glucan: one is to extract from cereal such as oats or solid fungi such as mushrooms directly; the second is through the liquid fermentation of fungi or bacteria, and through the extraction and processing of the fermentation liquid, to obtain β-glucan. In clinical oncology settings in Asia, parenteral formulations have also been used. A range of other potentially beneficial effects have been described, and oral forms of beta-glucans are widely available over-the-counter and online, while parenteral formulations are popular in parts of Asia and are the subject of ongoing trials worldwide.

---

2. Traditional and Historical Use

Pre-Modern and Ancient Use of Medicinal Mushrooms

Besides the pre-historical finding in the Italian Alps of a mushroom in possession of the Ice Man mummy discovered in 1991, possibly as a laxative for intestinal disease, the use of mushrooms as medicaments had already significantly spread in the cultures of ancient Greece, Rome, China, and India, and for centuries they have been part of the traditional oriental medicine. There is an approximately 5,000-year-old written Indian document about medicinal effects of mushrooms. Indian Ayurveda and traditional Chinese medicine can serve as examples of healing traditions developed through empirical experience.

As β-glucans are a structural component of mushrooms, their use as an unknown therapeutic in medicinal mushrooms dates back hundreds of years. Medicinal mushrooms, especially Coriolus versicolor (known as yun zhi in China), are commonly used in traditional Oriental medicine and have been for centuries. In the 1980s, the Japanese government approved the use of protein-bound polysaccharide (PSK), a beta-glucan compound found in mushrooms, for treating several types of cancers and for widespread use in cancer immunotherapy.

Cereal Grains in Traditional Diets

Historically, β-glucans have been integral to traditional diets and therapeutic practices, particularly in Asian medicine and European whole-grain consumption, due to their perceived immune-boosting properties. Cereal and fungal products have been used for centuries for medicinal and cosmetic purposes; however, the specific role of β-glucan was not explored until the 20th century.

The Scientific Discovery Timeline

Beta-glucans were first discovered in lichens, and shortly thereafter in barley. It was not until around 1941 when β-glucan began to be identified as a potent immune modulator in Western medicine. In a 1941 paper by Pillemer and Ecker, they described zymosan, a crude yeast cell wall preparation, that acted as a modulator of non-specific immune responses — which we now know as the complement system. Though at the time the active component of zymosan was unknown, it was later discovered that the active biological properties of zymosan were due mainly to β-glucan.

In 1961, Riggi and DiLuzio identified the active compound in zymosan to be a polysaccharide. They concluded that the polysaccharide required a 1,3 beta-type linkage for activity. Independently, concurrently in Japan, β-glucans were being investigated for antitumor properties, with the first study in 1969. A particular interest in oat β-glucan arose after a cholesterol-lowering effect from oat bran was reported in 1981. In 1997, the FDA approved a claim that intake of at least 3.0 g of β-glucan from oats per day decreased absorption of dietary cholesterol and reduced the risk of coronary heart disease.

---

3. Key Constituents and Active Compounds

β-D-Glucans belong to a group of physiologically active compounds called biological response modifiers and represent highly conserved structural components of cell walls in yeast, fungi, or seaweed. The biological activity of a particular β-glucan preparation is closely tied to its structural and physicochemical characteristics.

The characteristics of β-glucan, such as its molecular weight, molecular structure (backbone or side chain), solubility, and particle size, can influence the immunomodulatory effects of β-glucan.

Key named β-glucan compounds include:

• Lentinan: A β-1,3/1,6-glucan isolated from Lentinus edodes (shiitake mushroom), used intravenously in Japan for cancer support.
• PSK (Polysaccharide Kureha, Krestin): A form of mushroom-derived β-glucan used clinically in Japan to treat cancer, derived from Coriolus versicolor.
• Schizophyllan: A β-1,3/1,6-glucan from Schizophyllum commune, also used in Japan for gynecological cancers.
• Pleuran: A β-glucan isolated from Pleurotus ostreatus (oyster mushroom), studied for respiratory immune support.
• Curdlan: A linear β-1,3-glucan derived from bacteria, used in research settings.

---

4. Mechanisms of Action

Immune Receptor Engagement

Beta-glucans are well recognized for their ability to regulate immune responses through interactions with pattern recognition receptors (PRRs) such as Dectin-1, complement receptor 3 (CR3), and toll-like receptors (TLRs) on immune cells including macrophages, dendritic cells, and neutrophils.

For β-glucan to have an immunomodulatory effect, it must contain a β-1,3 glycosidic bond chain with a length of at least seven glucose units and β-1,6 glycosidic bonds in the side chain. It cannot be degraded by the mammalian digestive system and binds to macrophage membrane receptors Dectin-1 — an integral membrane protein of type II with a carbohydrate recognition domain akin to a C-type lectin — and TLR-2/6, a heterodimeric receptor complex involved in recognizing specific molecular patterns on pathogens and activating immune responses. It is then introduced into the cell by endosomes and fragmented. Different fragments attach to the CR3 membrane receptors of mononuclear cells, macrophages, dendritic cells, and natural killer cells, inducing the secretion of TNF-α and various cytokines.

The pattern recognition receptor Dectin-1 contains a single extracellular lectin-like carbohydrate recognition domain and a cytoplasmic tail with an immunoreceptor tyrosine-based activation-like motif (ITAM-like), which can initiate intracellular signalling upon engagement of β-glucans. The recognition of β-glucans by Dectin-1 induces numerous cellular responses, including phagocytosis, the respiratory burst, the production of arachidonic acid metabolites, and the induction of a number of cytokines and chemokines.

In addition to modulating the innate immune system, β-glucans influence the adaptive immune response. They enhance T cell activation, support regulatory T cell (Treg) function, and promote B cell antibody production, all crucial for maintaining immune balance and preventing autoimmune disease.

Macrophage Processing and Systemic Distribution

After oral administration, the specific backbone 1→3 linear beta-glycosidic chain of beta-glucans cannot be digested. Most beta-glucans enter the proximal small intestine and some are captured by macrophages. They are internalized and fragmented within the cells, then transported by the macrophages to the marrow and endothelial reticular system. The small beta-glucan fragments are eventually released by the macrophages and taken up by other immune cells, leading to various immune responses. Radiolabeled studies have verified that both small and large fragments of β-glucans are found in the serum, which indicates that they are absorbed from the intestinal tract.

Cholesterol-Lowering Mechanism

Beta-glucan, a viscous soluble fiber in oats, forms a gel in the gut that binds bile acids, forcing the liver to use more cholesterol to produce bile, thereby lowering circulating LDL levels. While beta-glucan viscosity was once considered the only mode of action, it is now evident that the fermentation products of beta-glucan and the associated gut microbial changes, as well as other components in oats, also play an important role.

Prebiotic and Gut Microbiome Interactions

The prebiotic potential of β-glucans is closely tied to their molecular structure, with specific β-1,3 and β-1,6 linkages providing substrate specificity for certain gut bacteria. These microbiota-mediated effects support host immunity, metabolic function, and intestinal homeostasis. Gut microbiome composition influences the immunomodulatory response to β-glucan; the proportions of the phylum Bacteroidota, family Muribaculaceae, and family Lactobacillaceae were significantly higher in high-immunomodulatory-effect subjects than in low-immunomodulatory-effect subjects. Furthermore, the genus Akkermansia was absent before the β-glucan diet and increased after a β-glucan diet. These microbes had the ability to metabolize β-glucan or were beneficial to health.

---

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Cholesterol Reduction

Evidence Strength: Strong (for oat and barley β-glucan at ≥3 g/day) — the area of strongest regulatory consensus.

Randomized controlled trials have consistently demonstrated that around 3 g of beta-glucan a day reduces total cholesterol by 0.25–0.66 mmol/L and LDL cholesterol by 0.24–0.6 mmol/L.

The EFSA Panel took into account 22 references, which included three meta-analyses and 19 randomised controlled trials. In weighing the evidence, the Panel found that most of the trials investigating the effects of oat beta-glucan at doses of at least 3 g/d have shown a statistically significant decrease in LDL-cholesterol concentrations, and that there was strong evidence supporting the biological plausibility of the effect. The Panel concluded that a cause and effect relationship has been established between the consumption of oat beta-glucan and lowering of blood LDL-cholesterol concentrations.

For barley β-glucan, one meta-analysis including 11 RCTs and one additional RCT investigating the effects of barley beta-glucans at doses of at least 3 g/day showed a decrease in total and LDL-cholesterol concentrations in both normo- and hypercholesterolaemic subjects, and the mechanism by which barley beta-glucans could exert the claimed effect is biologically plausible. The EFSA Panel concluded that a cause and effect relationship has been established between the consumption of barley beta-glucans and the lowering of blood LDL-cholesterol concentrations.

The wealth of evidence supporting beta-glucans has resulted in the FDA approving the health claim: "consumption of 3g or more per day of beta-glucan soluble fibre from either whole oats or barley, or a combination of whole oats and barley, as part of a low saturated fat and cholesterol diet, may reduce the risk of heart disease." In 2011 and 2012, the EFSA also approved a claim for 3 g daily of beta-glucan from barley or oats to lower blood cholesterol.

The U.S. Food and Drug Administration approved the first-ever health claim for oat beta-glucan in 1997, linking soluble fiber from whole oats, oat bran, and oat flour to reduced coronary heart disease risk when part of a low-saturated fat diet.

5.2 Blood Glucose Regulation and Diabetes

Evidence Strength: Moderate for postprandial glucose; mixed for fasting glucose in non-diabetic individuals; more positive in type 2 diabetes patients.

A meta-analysis of four articles dealing with a total of 350 type 2 diabetes patients found that T2DM patients administered oat β-glucan (OBG) from 2.5 to 3.5 g/day for 3 to 8 weeks presented significantly lowered concentrations in fasting plasma glucose (FPG) by −0.52 mmol/L (p = 0.01) and glycosylated hemoglobin (HbA1c) by −0.21% (p = 0.03). However, OBG intake did not significantly lower the fasting plasma insulin concentration. The authors concluded that moderate-term OBG intake (3–8 weeks) favoured glycaemic control of T2DM patients but did not improve their insulin sensitivity.

However, in hypercholesterolaemic (but not specifically diabetic) populations, findings are less consistent. A systematic review and meta-analysis of twelve trials with a total of 603 subjects found that beta-glucan consumption did not significantly affect measures of glycemic control in hypercholesterolaemic individuals. Summary estimates of weighted mean differences (WMD) and 95% confidence intervals were 0.05 mmol/L (−0.11, 0.02) for fasting glucose concentration and 0.75 pmol/L (−1.82, 3.32) for fasting insulin concentrations. Evidence from animal and observational studies has supported the beneficial effects of beta-glucan intake on glycemic control, but intervention studies in hypercholesterolaemic populations have generated mixed results.

Additionally, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies addressed "the scientific substantiation of health claims in relation to β-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations, increase in satiety leading to a reduction of postprandial glycaemic responses, and digestive function" in 2011.

5.3 Immune System Modulation

Evidence Strength: Moderate in preclinical models; growing but still preliminary in human trials; results are inconsistent across study designs and β-glucan sources.

The immune-modulating effects of β-glucan are attributed to the ability to bind to pattern recognition receptors including complement receptor 3, scavenger receptors, lactosylceramide, and Dectin-1, which results in activation of different aspects of the immune response depending on the cell types and species involved, although there is some controversy about the relative importance of each of these receptors. Most of the available evidence comes from preclinical data and human studies are just beginning to appear in the literature, therefore firm conclusions on clinical importance cannot yet be made.

The immunomodulatory effect of β-glucans (a syrup containing the pleuran β-glucan from Pleurotus ostreatus and vitamin C) was tested versus vitamin C alone in a clinical trial in children with recurrent respiratory tract infections; respiratory symptoms were reduced, but the beneficial effect cannot be attributed to the β-glucans alone and should rather be related to a potentiating effect by β-glucan of vitamin C. A shiitake mushroom extract (Lentinex®) given as a supplement in a cross-over, placebo-controlled trial in healthy elderly was safe and induced an increase in the number of circulating B-cells, without affecting any other immune parameter.

A 2014 randomized open-label crossover pilot study published in PubMed (NCT01727895) concluded that the study did not support the use of oral β-glucan to enhance innate immune responses in humans, with primary outcome measure of TNF-α secretion by ex vivo LPS-stimulated peripheral blood mononuclear cells showing no significant effect.

5.4 Cancer — Adjuvant Use

Evidence Strength: Preliminary and inconsistent in human clinical trials; stronger evidence exists for the use of specific fungal β-glucans (PSK, lentinan) as adjuvants in Japan, though results are mixed.

The antitumor effects of β-glucans, extracted from different sources, have been extensively studied in vitro as well as in animal-based in vivo studies; however, human-based clinical trials have rarely been reported.

Several forms of mushroom-derived β-glucans are used clinically in Japan to treat cancer, including polysaccharide Kureha (PSK, from Coriolus versicolor), lentinan, and schizophyllan. In randomized trials in Japan, PSK and schizophyllan have moderately improved survival rates in some cancer trials, and have been less encouraging in others.

Most clinical trials have been testing registered β-glucan extracts from yeast, such as ImmuCell™ WBG or BTH1677 (Imprime PGG), in combination with PD-1 blocking antibody or immune checkpoint inhibitors or with conventional treatments. Few of these studies have been completed and the results published so far support that these products are well tolerated and safe, and could improve the remission rate as first-line treatment combined with conventional chemotherapy in non-small cell lung carcinoma patients.

The most promising evidence to date in clinical trials has come from studies investigating the benefits of β-glucan in combination with conventional cancer treatment, on therapy side effects, quality of life, and survival of cancer patients. The majority of these studies investigated changes in patients' immune system by monitoring surrogate markers such as leukocyte counts or cytokine profiles, as well as by measuring chemotherapy-associated side effects and indexes of quality of life. One of the most prominent effects described for the oral administration of β-glucans is the attenuation of chemotherapy-induced fall of leukocyte counts, paralleling numerical or functional changes of some specific immune cell populations.

As of the time of a 2009 PubMed review, no good-quality clinical trial data was available on assessing the effectiveness of purified beta-glucans among cancer patients, and this has remained a significant gap. More recent trials using yeast-derived β-glucans in combination with monoclonal antibodies show preliminary promise but have not yet established standard-of-care recommendations.

5.5 Respiratory Tract Infections

Evidence Strength: Preliminary, with some positive results from small trials; insufficient to draw firm conclusions.

A significant reduction in respiratory infections, such as otitis, flu, bronchitis, and laryngitis, was observed in clinical trials with pleuran (β-glucan from P. ostreatus). The syrup was well tolerated in children and no serious adverse effects were observed. These studies showed that β-glucans (pleuran) from P. ostreatus can be helpful in reducing respiratory tract infections in children with chronic respiratory disorders.

5.6 Gut Microbiota and Prebiotic Effects

Evidence Strength: Emerging; primarily animal and in vitro data with limited but growing human evidence.

Historically, β-glucans have been integral to traditional diets and therapeutic practices, particularly in Asian medicine and European whole-grain consumption, due to their perceived immune-boosting properties. More mechanistically, the prebiotic potential of β-glucans is closely tied to their molecular structure, with specific β-1,3 and β-1,6 linkages providing substrate specificity for certain gut bacteria, and these microbiota-mediated effects support host immunity, metabolic function, and intestinal homeostasis.

---

6. Dosage Forms and Study-Reported Dosages

For lowering cholesterol, taking oat or barley beta-glucans orally at a dosage of at least 3 grams daily is the dose established in clinical literature. If choosing to supplement with whole foods, this can also be achieved with about 75 grams (2.6 oz) of whole grain oats, 55 grams (2 oz) of oat bran, or 45 grams (1.6 oz) of barley.

The efficient daily dose of 3 g β-glucan can be obtained from 75 g of whole grain oats (minimum 5.5% β-glucan) or 55 g of oat bran (4% β-glucan).

For reducing post-meal increases in blood glucose and insulin levels, adding around 3 grams (0.1 oz) of oat beta-glucans per 30 grams (1 oz) of carbohydrates has been reported as effective in studies.

For reducing the incidence and duration of upper respiratory tract infections, taking yeast beta-glucans orally at a dosage of 250 mg daily for at least 4 weeks has been the dosage used in some positive trials.

In the T2DM meta-analysis, oat β-glucan was administered from 2.5 to 3.5 g/day for 3 to 8 weeks.

Parenteral formulations — such as intravenous lentinan — are popular in parts of Asia and are the subject of ongoing trials worldwide.

Although collectively termed beta-glucans, variations in composition exist because of derivation from different natural sources; batch variations also occur due to differing growth conditions.

---

7. Safety Considerations and Drug Interactions

General Safety Profile

The FDA granted baker's yeast beta-glucan "Generally Recognized as Safe" (GRAS) status in 2008, allowing it as an ingredient in baked goods, beverages, cereals, dairy products, soups, and more at up to 200 milligrams per serving. The European Food Safety Authority followed with its own safety clearance in 2011. These designations mean regulatory scientists reviewed the available toxicology and human data and found no meaningful safety concerns at typical intake levels.

Adverse Effects

The most commonly reported side effects are mild digestive issues: nausea, diarrhea, and occasional vomiting. These tend to occur with soluble forms derived from yeast or fungi and are more likely at higher doses or when first starting supplementation.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Source-Specific Allergen Considerations

If a person has a confirmed yeast allergy, yeast-derived beta-glucan supplements could theoretically trigger a reaction, though most commercial products are highly purified and contain very little residual yeast protein. Oat-derived beta-glucan would be a safer choice in that case, provided the individual does not have a gluten sensitivity (oats are naturally gluten-free but often processed alongside wheat).

Drug Interactions

• Immunosuppressants: Beta-glucans may increase the activity of the immune system, and by doing so, might decrease the effectiveness of medications that decrease the immune system. Examples include azathioprine (Imuran), cyclosporine (Neoral, Sandimmune), tacrolimus (Prograf), sirolimus (Rapamune), prednisone, and other corticosteroids.
• Antihypertensive drugs: Beta-glucans might decrease blood pressure in some people. Taking beta-glucans along with medications used for lowering high blood pressure might cause blood pressure to drop too low. However, it is not known if this is a significant clinical concern.
• Indomethacin: Taking beta-glucans with the drug indomethacin might increase the risk of developing life-threatening side effects to indomethacin. Until more is known about this potential interaction, caution is warranted.

Inhalation Risk

A single-blind, randomized, controlled-exposure, crossover study conducted in 50 healthy adults identified an acute negative effect on blood pressure (i.e., increases) with inhalation of β-1,3-D-glucan particulate matter. In contrast to endotoxin, no effect on pulse pressure was observed with beta-glucan particulate matter.

Source and Batch Variability

Beta-glucans of different sizes and branching patterns may have significantly variable immune potency. Careful selection of appropriate beta-glucans is essential if we wish to investigate the effects of beta-glucans clinically. Variations in composition exist because of derivation from different natural sources, and batch variations also occur due to differing growth conditions.

---

8. Body Systems Associated with Beta-Glucan

• Cardiovascular system: Cholesterol reduction, LDL lowering, blood pressure modulation (established for oat/barley β-glucan)
• Immune system: The most promising evidence to date in human trials has come from recent studies on a benefit of β-glucan on quality of life and survival when given in combination with cancer treatment; β-glucans appear to be effective at enhancing immune function and reducing susceptibility to infection and cancer.
• Gastrointestinal system: Beta-glucan's biofunctional roles include immune modulation, cholesterol regulation, and gastrointestinal health, supported by clinical studies.
• Metabolic system: Beta-glucans may protect the cardiovascular system, ameliorating glucose, lipid metabolism, and blood pressure; these activities, observed for oat and barley β-glucans, require confirmation in human studies with mushroom β-glucans.
• Oncology (adjuvant): Used as an adjuvant in cancer immunotherapy in Japan; under investigation in combination with immune checkpoint inhibitors and monoclonal antibody therapies.

---

References

• Vetvicka V & Vetvickova J. β-Glucans, History, and the Present: Immunomodulatory Aspects and Mechanisms of Action. Journal of Immunotoxicology, 2008.
• Sima P, et al. Beta-Glucan as a Soluble Dietary Fiber Source: Origins, Biosynthesis, Extraction, Purification, Structural Characteristics, Bioavailability, Biofunctional Attributes, Industrial Utilization, and Global Trade. PMC, 2024.
• Cerletti C, Esposito S, Iacoviello L. Edible Mushrooms and Beta-Glucans: Impact on Human Health. Nutrients, 2021.
• Critical Review on the Impacts of β-Glucans on Gut Microbiota and Human Health. ScienceDirect, 2025.
• EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Oat Beta-Glucan and Lowering Blood Cholesterol. EFSA Journal, 2010.
• EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Barley Beta-Glucans and Lowering of Blood Cholesterol. EFSA Journal, 2011.
• Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. Journal of Hematology & Oncology, 2009.
• Akramiene D, et al. Immune modulating effects of β-glucan. PubMed, 2010.
• Mosikanon K, et al. The effects of orally administered Beta-glucan on innate immune responses in humans, a randomized open-label intervention pilot-study. PubMed, 2014.
• Giavasis I. Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer? PMC, 2020.
• Shen XL, et al. Effect of Oat β-Glucan Intake on Glycaemic Control and Insulin Sensitivity of Diabetic Patients: A Meta-Analysis of Randomized Controlled Trials. Nutrients, 2016.
• Chi H, et al. A systematic review and meta-analysis of beta-glucan consumption on glycemic control in hypercholesterolemic individuals. International Journal of Food Sciences and Nutrition, 2015.
• El Khoury D, et al. Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future. PMC, 2017.
• The Immunomodulatory Effect of β-Glucan Depends on the Composition of the Gut Microbiota. PMC, 2023.
• Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic. PMC, 2019.
• Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression. PMC, 2021.
• Beta-glucan. Wikipedia (citing primary peer-reviewed sources).
• Beta-Glucans benefits, dosage, and side effects. Examine.com.
• Bielak-Zmijewska A, et al. β-Glucans and their applications in cancer therapy: focus on human studies. PubMed, 2012.
• Wisitrassameewong K, et al. β-Glucans. MDPI Encyclopedia, 2021.
• Exploring the Properties and Application Potential of β-Glucan in Skin Care. PMC, 2025.
• Mechanistic insights into β-glucans and gut microbiota interactions for enhancing human health. Discover Food, Springer Nature, 2025.
• Beta-glucans: Health Benefits, Side Effects, Uses, Dose & Precautions. RxList.